BRAF and colorectal carcinoma: Subsequently, the phase 2 ANCHOR CRC study demonstrated an ORR of 47% in metastatic CRC with BRAF V600E treated in the first line with the encorafenib, binimetinib, and cetuximab triplet, suggesting that moving MAPK-targeted therapies to the first line may yield benefits for these patients [19].